Navigation Links
Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
Date:1/30/2008

gory. The Company's flagship product, Zicam Cold Remedy nasal gel, is a patented, homeopathic remedy that has been clinically proven to reduce the duration and severity of the common cold. In studies published in the October 2000 issue of ENT -- Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM: An International Journal of Medicine, the Zicam Cold Remedy product was shown to reduce the duration of the common cold. The Company also manufactures and markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy Chewables(TM); Zicam Cold Remedy Oral Mist(TM); Zicam Cold Remedy RapidMelts(TM); Zicam Allergy Relief; Zicam Cold Remedy Swabs(TM); Zicam Extreme Congestion Relief; Zicam Sinus Relief; as well as Zicam Cough products and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to http://www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at http://www.matrixxinc.com. For additional information, contact William Hemelt, Chief Financial Officer, 602-385-8888, or Bill Barba, Treasurer, at 602-385-8881. Matrixx is located at 4742 N. 24th Street, Suite 455, Phoenix, Arizona 85016.

Matrixx Initiatives, Inc. Forward-Looking Statement Disclaimer:

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "plan," "anticipate," and other similar statements of expectation identify forward-looking statements and include statements regarding: (i) our net sales and net income expectations for the fiscal year ending March
'/>"/>

SOURCE Matrixx Initiatives, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
2. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
3. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
6. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
7. Encision Reports Third Fiscal Quarter Results
8. Zimmer Reports Fourth Quarter and 2007 Financial Results
9. Amylin Pharmaceuticals Reports 2007 Financial Results
10. Cystic Fibrosis Foundation reports upward trend for key health outcomes
11. NBTY Reports First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Nutritional science and medical research has enabled ... health conditions and illnesses linked to carrying excess weight. ... eating methods to rid the body of dangerous toxins, ... fast and processed foods. Patients find the company’s ... report feeling better and losing excess fat within days. ...
(Date:5/5/2015)... In a April 25, 2015, report published ... the Missouri State Highway Patrol (MSHP) announced that Indiana led ... for the second year in a row. , The ... 1,469 incidents in 2014 alone, around 15% of the national ... the US Population calls Indiana home, according to the report. ...
(Date:5/5/2015)... Information Innovators Inc. (“Triple-i”), ... government, today announced its acquisition of Creative ... exclusively to federal government customers through its highly ... health services, and program management support. The company ... a Third Party Assessment Organization (3PAO) for cloud ...
(Date:5/5/2015)... Freeport, Grand Bahama (PRWEB) May 05, 2015 ... published its Orthopedic Lifestyle Report today. The study was ... orthopedic conditions such as osteoarthritis and sports-related ... chronic pain and stiffness was the most prevalent symptom ... reduced functionality such as walking, standing and bending over. ...
(Date:5/5/2015)... 2015 Barnabas Health, the state’s largest ... a new healthy cooking video series starring celebrity chef ... Bravo’s Top Chef, teamed up with Barnabas Health to ... living. In support of the series, Barnabas Health ... videos will be showcased on social media. ...
Breaking Medicine News(10 mins):Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:Barnabas Health Teams Up With Celebrity Chef Sam Talbot To Launch "Life Is Better Healthy" Cooking Video Series 2Health News:Barnabas Health Teams Up With Celebrity Chef Sam Talbot To Launch "Life Is Better Healthy" Cooking Video Series 3
... the most dependent on,others and the ones the least ... expert. "Why do children exhibit psychological trauma? There ... of their parents and the predictability,of their physical environment. ... psychologist Robert R. Butterworth, Ph.D. Dr. Butterworth added, ...
... Komen Detroit Race for the Cure Joins Nationwide Campaign ... Deadlier for Low-Income Women and Women of Color, ... Cure,physicians and executives from five of metro Detroit,s top ... cancer survivors,and advocates this evening at a "Close the ...
... children with attention deficit hyperactivity disorder (ADHD) at the ... missing: the fathers., Fabiano, an assistant professor in the Graduate ... graduate assistant at the UB Center for Children and ... helped more than 2,500 children with behavioral, emotional and ...
... Conference Call to be held on November 13, 2007 ... / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong), ... Inc. (NYSE: WX ) ("WuXi PharmaTech" or "the ... company, today announced that it will release unaudited,financial results ...
... Science,Corporation (Nasdaq: CSCX ), a global leader ... that it will release its third,quarter 2007 financial ... close. The Company has scheduled a conference call ... to discuss the financial results for,the third quarter ...
... discovery of suitable molecular targets cellular molecules along ... comes the perplexing dilemma of where to find ... those targets. While the possibilities for drug designs are ... are often problematic or ill-suited for the particular needs ...
Cached Medicine News:Health News:California Wildfires - Psychological Effects; Children ... Psychologist Is Available to Discuss Trauma 2Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 2Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 3Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 4Health News:Getting fathers involved in children's ADHD treatment programs 2Health News:Getting fathers involved in children's ADHD treatment programs 3Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 3Health News:Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 3Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 4Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 5Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 6Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 7Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 8
(Date:5/5/2015)... FREMONT, Calif. , May 5, 2015 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and ... 2a clinical trial evaluating tenapanor in Stage 3 ... mellitus and albuminuria did not meet the primary ... tenapanor-treated patients compared to patients receiving placebo. ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - ... Laval and known under the « ... the closing of the transaction previously announced on April ... issued and outstanding  shares of Orthoconcept (2008) inc.   ... 500 000 common shares (TSXV: ERG) to the vending ...
(Date:5/5/2015)... -- The preclinical contract research organization Absorption Systems , ... safety testing of medical devices, announces that Dr. ... at this week,s annual meeting of The Association for ... Denver, CO. The title of Dr. Gum,s ... Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer in a Rabbit ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... aureus and, Methicillin-Resistant Staphylococcus aureus from Positive ... BD Diagnostics, a segment,of BD (Becton, Dickinson and ... it,received clearance from the U.S. Food and Drug ... new assay is the first test available to,rapidly ...
... Dec. 27 Allos,Therapeutics, Inc. (Nasdaq: ALTH ... (DMC) has completed the pre-specified 65-patient,safety review of ... trial of,PDX (pralatrexate) in patients with relapsed or ... the trial continue per the,protocol. This interim assessment ...
Cached Medicine Technology:BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 2BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
The ToxCup Drug Screen Cup is a one-step test for the rapid detection of up to five drugs of abuse and four adulteration tests. It's design integrates sample collection, drug/adulteration testing and...
Lasts up to 3 months , Absorbable copolymer of glycolic acid and trimethylene carbonate , Designed to provide relief from short term dry eye conditions. , Appropriate for surgery-related d...
... transconjunctival self-retaining infusion cannulas for use in ... some benefit to patients that present with ... lessening the occurrence of suture induced astigmatism. ... and does not require a blade for ...
Medicine Products: